Vor Biopharma Inc Surges on Market Strength
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 09 Dec 25
Source: 8-K
Vor Biopharma Inc experienced a significant price increase of 45.93%, crossing above its 20-day SMA amid positive market conditions.
The Nasdaq-100 is slightly down, while the S&P 500 shows minor gains, indicating a mixed market backdrop. However, Vor Biopharma's strong performance stands out.
This upward movement may attract further investor interest, suggesting potential for continued growth in the near term.
Analyst Views on VOR
Wall Street analysts forecast VOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VOR is 38.67 USD with a low forecast of 9.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 13.740
Low
9.00
Averages
38.67
High
55.00
Current: 13.740
Low
9.00
Averages
38.67
High
55.00
About VOR
Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
